Schlaberg Robert, Ampofo Krow, Tardif Keith D, Stockmann Chris, Simmon Keith E, Hymas Weston, Flygare Steven, Kennedy Brett, Blaschke Anne, Eilbeck Karen, Yandell Mark, McCullers Jon A, Williams Derek J, Edwards Kathryn, Arnold Sandra R, Bramley Anna, Jain Seema, Pavia Andrew T
Department of Pathology.
ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah.
J Infect Dis. 2017 Sep 15;216(6):688-696. doi: 10.1093/infdis/jix352.
The role of human bocavirus (HBoV) in respiratory illness is uncertain. HBoV genomic DNA is frequently detected in both ill and healthy children. We hypothesized that spliced viral capsid messenger RNA (mRNA) produced during active replication might be a better marker for acute infection.
As part of the Etiology of Pneumonia in the Community (EPIC) study, children aged <18 years who were hospitalized with community-acquired pneumonia (CAP) and children asymptomatic at the time of elective outpatient surgery (controls) were enrolled. Nasopharyngeal/oropharyngeal specimens were tested for HBoV mRNA and genomic DNA by quantitative polymerase chain reaction.
HBoV DNA was detected in 10.4% of 1295 patients with CAP and 7.5% of 721 controls (odds ratio [OR], 1.4 [95% confidence interval {CI}, 1.0-2.0]); HBoV mRNA was detected in 2.1% and 0.4%, respectively (OR, 5.1 [95% CI, 1.6-26]). When adjusted for age, enrollment month, and detection of other respiratory viruses, HBoV mRNA detection (adjusted OR, 7.6 [95% CI, 1.5-38.4]) but not DNA (adjusted OR, 1.2 [95% CI, .6-2.4]) was associated with CAP. Among children with no other pathogens detected, HBoV mRNA (OR, 9.6 [95% CI, 1.9-82]) was strongly associated with CAP.
Detection of HBoV mRNA but not DNA was associated with CAP, supporting a pathogenic role for HBoV in CAP. HBoV mRNA could be a useful target for diagnostic testing.
人博卡病毒（HBoV）在呼吸道疾病中的作用尚不确定。在患病和健康儿童中均经常检测到HBoV基因组DNA。我们推测，在病毒活跃复制过程中产生的剪接病毒衣壳信使核糖核酸（mRNA）可能是急性感染的更好标志物。
作为社区获得性肺炎病因学（EPIC）研究的一部分，纳入了年龄小于18岁、因社区获得性肺炎（CAP）住院的儿童以及择期门诊手术时无症状的儿童（对照组）。通过定量聚合酶链反应检测鼻咽/口咽标本中的HBoV mRNA和基因组DNA。
在1295例CAP患者中，10.4%检测到HBoV DNA，721例对照组中7.5%检测到HBoV DNA（优势比[OR]为1.4[95%置信区间{CI}，1.0 - 2.0]）；HBoV mRNA的检测率分别为2.1%和0.4%（OR为5.1[95%CI，1.6 - 26]）。在对年龄、入组月份和其他呼吸道病毒检测进行校正后，HBoV mRNA检测（校正后OR为7.6[95%CI，1.5 - 38.4]）而非DNA检测（校正后OR为1.2[95%CI，0.6 - 2.4]）与CAP相关。在未检测到其他病原体的儿童中，HBoV mRNA（OR为9.6[95%CI，1.9 - 82]）与CAP密切相关。
HBoV mRNA而非DNA的检测与CAP相关，支持HBoV在CAP中的致病作用。HBoV mRNA可能是诊断检测的有用靶点。
